Show simple item record

dc.contributor.authorBerkeley, RAen_US
dc.contributor.authorSteele, LPen_US
dc.contributor.authorMulder, AAen_US
dc.contributor.authorvan den Wollenberg, DJMen_US
dc.contributor.authorKottke, TJen_US
dc.contributor.authorThompson, Jen_US
dc.contributor.authorCoffey, Men_US
dc.contributor.authorHoeben, RCen_US
dc.contributor.authorVile, RGen_US
dc.contributor.authorMelcher, Aen_US
dc.contributor.authorIlett, EJen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2019-02-26T11:47:38Z
dc.date.issued2018-10en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30209061en_US
dc.identifier2326-6066.CIR-18-0309en_US
dc.identifier.citationCancer Immunol Res, 2018, 6 (10), pp. 1161 - 1173en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3096
dc.identifier.eissn2326-6074en_US
dc.identifier.doi10.1158/2326-6066.CIR-18-0309en_US
dc.description.abstractImmunotherapy is showing promise for otherwise incurable cancers. Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. However, OVs also stimulate antiviral immune responses, including the induction of OV-neutralizing antibodies. Current dogma suggests that the presence of preexisting antiviral neutralizing antibodies in patients, or their development during viral therapy, is a barrier to systemic OV delivery, rendering repeat systemic treatments ineffective. However, we have found that human monocytes loaded with preformed reovirus-antibody complexes, in which the reovirus is fully neutralized, deliver functional replicative reovirus to tumor cells, resulting in tumor cell infection and lysis. This delivery mechanism is mediated, at least in part, by antibody receptors (in particular FcγRIII) that mediate uptake and internalization of the reovirus/antibody complexes by the monocytes. This finding has implications for oncolytic virotherapy and for the design of clinical OV treatment strategies. Cancer Immunol Res; 6(10); 1161-73. ©2018 AACR.en_US
dc.format.extent1161 - 1173en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleAntibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-08-16en_US
rioxxterms.versionofrecord10.1158/2326-6066.CIR-18-0309en_US
rioxxterms.licenseref.startdate2018-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCancer Immunol Resen_US
pubs.issue10en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.publication-statusPublisheden_US
pubs.volume6en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTranslational Immunotherapyen_US
dc.contributor.icrauthorMelcher, Alanen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record